Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is for investigation and collection of Aricept safety information with a dose increase on Alzheimer's disease patients.
This is an observational study to systematically investigate domestic patients with Alzheimer's disease to figure out the safety under a situation of the use of Donepezil HCl 23mg. Additionally, if the dose of Donepezil HCl increase, there is need to examine the safety of Donepezil HCl 23mg in depth for patients with Alzheimer's disease by comparing aspects of occurring adverse events by the type of Donepezil HCl increase.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aricept Group 1 | Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept |
| |
| Aricept Group 2 | Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aricept | Drug | 5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability due to an increase of Aricept in patients with Alzheimer's disease. | The aspects of adverse events between those who have increased Aricept dosage from 5mg to 10mg and those who have increased Aricept dosage from 10mg to 23mg will be compared. The subjects will be observed at least more than 12 weeks after Aricept administration. The patients who have obtained safety information through a visit after Aricept administration at least once will be selected as the subjects who can be assessed under the status of use. | Up to 12 Weeks |
Not provided
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Patients with Alzheimer's disease
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Busan | South Korea | |||||
Not provided
Not provided
Not provided
Not provided
| Chungcheongbuk-do |
| South Korea |
| Chungcheongnam-do | South Korea |
| Daegu | South Korea |
| Gangwon-do | South Korea |
| Gwangju | South Korea |
| Gyeonggji-do | South Korea |
| Gyeongsangbuk-do | South Korea |
| Gyeongsangnam-do | South Korea |
| Jeju-do | South Korea |
| Jeollabuk-do | South Korea |
| Jeollanam-do | South Korea |
| Seoul | South Korea |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077265 | Donepezil |
| ID | Term |
|---|---|
| D007189 | Indans |
| D007192 | Indenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided